CTLA4 and non-small cell lung carcinoma: In a retrospective study, the PFS of NSCLC in the stereotactic body radiation therapy (SBRT) combined anti-PD-1 group was better than that in the SBRT combined anti-CTLA4 group at 18 months (p = 0.02), but the OS was comparable between the two groups at 18 months (p = 0.08)(Chen et al. 2020).